Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 5/20 | 0.48 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | TASP1 | Q9H6P5 | 1/20 | 0.43 |
| ▸ | BMP1 | P13497 | 1/20 | 0.42 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.42 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31497334 | 0.98 | ERBB2 (0.49) | BACE1BACE2ERBB2PTPN1KEAP1 | |
| SCHEMBL31497337 | 0.97 | ERBB2 (0.50) | BACE1BACE2ERBB2PTPN1KEAP1 | |
| SCHEMBL31497372 | 0.96 | BACE1 (0.48) | BACE1BACE2ERBB2PTPN1KEAP1 | |
| SCHEMBL31497322 | 0.96 | BACE1 (0.48) | BACE1BACE2ERBB2PTPN1KEAP1 | |
| SCHEMBL31497354 | 0.94 | PTPN1 (0.53) | BACE1BACE2ERBB2PTPN1KEAP1 | |
| SCHEMBL31497375 | 0.93 | ERBB2 (0.48) | BACE1BACE2ERBB2PTPN1KEAP1 | |
| SCHEMBL31497324 | 0.92 | ERBB2 (0.48) | BACE1BACE2ERBB2PTPN1KEAP1 | |
| SCHEMBL31497319 | 0.92 | SIRT2 (0.47) | BACE1BACE2ERBB2PTPN1KEAP1 | |
| SCHEMBL31497342 | 0.91 | PTPN1 (0.52) | BACE1BACE2PTPN1TASP1BMP1 | |
| SCHEMBL31497376 | 0.91 | ERBB2 (0.51) | BACE1BACE2ERBB2SIRT2SIRT5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388623-A1 | PEPTIDE INHIBITOR AND USE THEREOF | CHENGDU BRILLIANT INSPIRATION BIOTHERAPEUTICS CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| EP-4545551-A1 | PEPTIDE INHIBITOR AND USE THEREOF | Chengdu Brilliant Inspiration Biotherapeutics Co., Ltd (CN) | 2025-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388623-A1 | PEPTIDE INHIBITOR AND USE THEREOF | VIP, TGFB1, FN1 | BACE1 924/4885BACE2 2644/4885ERBB2 3650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.